Home
>
US Stocks
>
Albireo Pharma Inc
Albireo Pharma Inc
ALBO

Albireo Pharma Inc (ALBO)

$29.231.99%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
28.86
Today Low/High
28.86 / 29.54
52 Week Low/High
$25.38 / $49
P/E ratio
-4.1308
Market Cap
$560.54M

Company Details

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Organisation
Albireo Pharma Inc
Headquaters
Boston, Massachusetts, US
Employees
90
Industry
Health Technology
CEO
Gary Gemignani

Discover more

Frequently Asked Questions

What is Albireo Pharma Inc (ALBO) share price today?

Can Indians buy Albireo Pharma Inc (ALBO) shares?

How can I buy Albireo Pharma Inc (ALBO) shares from India?

Can Fractional shares of Albireo Pharma Inc (ALBO) be purchased?

What are the documents required to start investing in Albireo Pharma Inc (ALBO) stocks?

We are a SEBI registered investement advisor